目的探讨新的和严重药物不良反应(adverse drug reactions,ADRs)的临床特征,为安全用药提供依据。方法回顾分析广州市胸科医院2020—2024年上报的279例新的和严重的ADRs病例,收集ADRs的报告类型、累及器官、患者年龄和性别、所涉药物种...目的探讨新的和严重药物不良反应(adverse drug reactions,ADRs)的临床特征,为安全用药提供依据。方法回顾分析广州市胸科医院2020—2024年上报的279例新的和严重的ADRs病例,收集ADRs的报告类型、累及器官、患者年龄和性别、所涉药物种类及剂型等信息,进行特征与规律分析。结果病例以严重ADRs为主(63.8%),男性占比57.3%(男∶女=1.34∶1),45岁以上患者占63.1%。涉及12类96种药物,抗感染药物占比75.0%,口服给药(65.1%)和静脉滴注(32.6%)为主要的给药方式。消化系统损害最常见(39.1%),其次为皮肤及其附件损害(12.3%)、血液系统(10.5%)及神经系统损害(9.6%)。结论ADR发生与年龄、给药方式等多因素相关,临床需加强多学科协作,强化用药监护与ADR监测,确保用药安全。展开更多
A sensitive,rapid,and robust ultra-high performance liquid chromatography-tandem mass spectrometry(UHPLC-MS/MS)method was established for the first time to quantify agarotriose(A3)in rat plasma,tissues,urine,and feces...A sensitive,rapid,and robust ultra-high performance liquid chromatography-tandem mass spectrometry(UHPLC-MS/MS)method was established for the first time to quantify agarotriose(A3)in rat plasma,tissues,urine,and feces.A3 and stachyose(internal standard)were separated by a BEH amide column at 65℃under the mobile phase of 10 mmol L^(-1)ammonium ace-tate-acetonitrile(42:58,v/v)with 350µLmin-1.The acquisition of transitions was carried out in multiple reaction monitoring(MRM)pattern operating with positive ionization at m/z 509.16>329.15 for A3 and m/z 689.15>527.11 for stachyose.The linearity ranges of A3 were 10 to 5000nmolL^(-1)for plasma,20 to 10000nmolL^(-1)for tissues,and 40 to 20000nmolL^(-1)for urine and feces.The accuracy and precision ranged from 90.9%to 111.6%and 0.7%to 10.1%,respectively.The stability was between 86.1%and 102.5%.The extraction recovery was consistent and reproducible.The matrix effect ranged from 1.5%to 11.4%.The pharmacokinetic,tissue dis-tribution,and excretion studies were successfully conducted with the validated method.Results showed that A3 could be absorbed by rats,and the absolute bioavailability was 6.7%.Furthermore,it was rapidly distributed in rat tissues and mainly eliminated via feces excretion(67.0%)after oral administration.For intravenous bolus,85.5%was recovered,and renal excretion was the primary path-way(77.6%)for cumulative recovery.展开更多
文摘目的探讨新的和严重药物不良反应(adverse drug reactions,ADRs)的临床特征,为安全用药提供依据。方法回顾分析广州市胸科医院2020—2024年上报的279例新的和严重的ADRs病例,收集ADRs的报告类型、累及器官、患者年龄和性别、所涉药物种类及剂型等信息,进行特征与规律分析。结果病例以严重ADRs为主(63.8%),男性占比57.3%(男∶女=1.34∶1),45岁以上患者占63.1%。涉及12类96种药物,抗感染药物占比75.0%,口服给药(65.1%)和静脉滴注(32.6%)为主要的给药方式。消化系统损害最常见(39.1%),其次为皮肤及其附件损害(12.3%)、血液系统(10.5%)及神经系统损害(9.6%)。结论ADR发生与年龄、给药方式等多因素相关,临床需加强多学科协作,强化用药监护与ADR监测,确保用药安全。
基金funded by the Fundamental Research Funds for the Central Universities(Nos.201912008,201964019)the Natural Science Foundation of Shandong Province(No.ZR2019BC025).
文摘A sensitive,rapid,and robust ultra-high performance liquid chromatography-tandem mass spectrometry(UHPLC-MS/MS)method was established for the first time to quantify agarotriose(A3)in rat plasma,tissues,urine,and feces.A3 and stachyose(internal standard)were separated by a BEH amide column at 65℃under the mobile phase of 10 mmol L^(-1)ammonium ace-tate-acetonitrile(42:58,v/v)with 350µLmin-1.The acquisition of transitions was carried out in multiple reaction monitoring(MRM)pattern operating with positive ionization at m/z 509.16>329.15 for A3 and m/z 689.15>527.11 for stachyose.The linearity ranges of A3 were 10 to 5000nmolL^(-1)for plasma,20 to 10000nmolL^(-1)for tissues,and 40 to 20000nmolL^(-1)for urine and feces.The accuracy and precision ranged from 90.9%to 111.6%and 0.7%to 10.1%,respectively.The stability was between 86.1%and 102.5%.The extraction recovery was consistent and reproducible.The matrix effect ranged from 1.5%to 11.4%.The pharmacokinetic,tissue dis-tribution,and excretion studies were successfully conducted with the validated method.Results showed that A3 could be absorbed by rats,and the absolute bioavailability was 6.7%.Furthermore,it was rapidly distributed in rat tissues and mainly eliminated via feces excretion(67.0%)after oral administration.For intravenous bolus,85.5%was recovered,and renal excretion was the primary path-way(77.6%)for cumulative recovery.
